| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697030 | Brachytherapy | 2017 | 7 Pages |
Abstract
D2cc is associated with the occurrence of LRT in HDRBT-treated prostate cancer patients. The dose constraints proposed and recommended by experienced HDRBT centers must be investigated to determine the threshold dose through long-term and prospective studies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Rodolfo Chicas-Sett, Dolores Farga, Maria J. Perez-Calatayud, Francisco Celada, Susana Roldan, Victoria Fornes-Ferrer, Blanca Ibanez-Rosello, Alejandro Tormo, Jose M. Benlloch, Jose Perez-Calatayud,